IDH.L Regulatory News (IDH)

13 Mar 2007 07:00

Immunodiagnostic Systems Hldgs PLC13 March 2007 Immunodiagnostic Systems Holdings PLC ("IDS" or the "Company") PLC Board Appointment and Appointment of new CEO at IDS GmbH IDS, a leading producer of diagnostic testing kits, announces Anthony "Tony"Wilks, aged 47, has been elected to the main Board of IDS Holdings plc. Havingjoined IDS in November 2004 to establish IDS GmbH in Frankfurt, Mr Wilks thenrelocated from Frankfurt to Newcastle upon Tyne to re-organize and lead theSales & Marketing function at IDS, bolstering the staff in the German office ashe did so. He now takes on responsibility for global Sales & Marketing at IDS, where hisextensive experience of laboratory automation and the marketing of capitalequipment, gained in senior appointments within the In Vitro Diagnostics (IVD)industry with Tosoh and Nichols Institute Diagnostics, will further enhance thecompany's prime strategic direction. The development and future launch of automated diagnostic products and theassociated instrumentation became a key objective of IDS following the signatureof an agreement with BioCode-Hycel of Liege, Belgium on 4th December 2006. Thisagreement grants IDS exclusive global rights to develop Bone & Skeletalbiomarker tests for the BioCode-Hycel 3X3 fully-automated analyser. Also announced today is the appointment of Dr Rudolf Schemer to the post of CEO(GeschTMaftsfuhrer) at IDS GmbH in Frankfurt. Dr Schemer, aged 46, gained his Doctorate (PhD) from the University of Hohenheim(Stuttgart, Germany) in 1991, before joining Nichols Institute Diagnostics in atechnical sales position. His ensuing progression to Sales & Marketing Manager,then European Marketing Manager, before becoming Country Manager (Germany, UK,Ireland, The Netherlands, Austria & Switzerland) followed his success in placingover 150 fully automated specialty immunoassay systems, and in maintaining andgrowing these high-value accounts. Dr Schemer also has specific sector expertise in growth hormones, insulin-likegrowth factors, and their binding proteins, and has an extensive network ofcollaborating clinicians and scientists throughout Europe and the USA. Tony Wilks commented: "IDS GmbH is now well-established and growing, and securing the services of DrSchemer to take it further forward is a real achievement. Rudolf and I haveworked closely together in the past, and have an intimate understanding of theassay automation market. In my expanded role as group Sales & MarketingDirector, I will be co-ordinating our marketing activities with Biocode-Hycel,as well as directing IDS' activities in the UK, USA, Germany and France, andthose of our Distributors elsewhere. We have a great team in place, and I'mlooking forward to us collectively meeting the challenges ahead". Managing Director of IDS, Dr Roger Duggan, said: "We are going from strength to strength in every aspect of our business, at homeand abroad. The very high calibre of experienced professionals now on board,and those seeking to join us, is very gratifying, and gives us great confidencein our ability to meet the demanding targets we set ourselves. We will go intoFY2007/8 in fine spirits!" There is no further information to disclose in respect of Tony Wilks underparagraph (f) of schedule 2 to the AIM rules. Enquiries:Immunodiagnostic Systems Holdings plc Parkgreen Communications LtdDr. Roger Duggan, Managing Director Paul McManusTel: 0191 519 0660 Tel: 020 7479 7933www.idsltd.com Mob: 07980 541 893 This information is provided by RNS The company news service from the London Stock Exchange